# Magnesium Replacement and Hyperglycemia After Kidney Transplantation

> **NCT04382157** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Oslo University Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Hypomagnesemia
- Kidney Transplantation

## Interventions

- **DRUG:** Mablet 360 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04382157
- **Lead sponsor:** Oslo University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-02-25
- **Primary completion:** 2022-08-31
- **Final completion:** 2022-08-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2021-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04382157

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04382157, "Magnesium Replacement and Hyperglycemia After Kidney Transplantation". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04382157. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*